KalVista Pharmaceuticals (KALV) EBIT (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported EBIT of -$59.0 million for Q3 2025, down 33.46% on a YoY basis from -$88.7 million in Q3 2024, and down 7.23% sequentially from -$55.0 million in Q2 2025.
KalVista Pharmaceuticals (KALV) EBIT (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of EBIT data on file, last reported at -$59.0 million in Q3 2025.
- For the quarter ending Q3 2025, EBIT fell 33.46% year-over-year to -$59.0 million; the trailing twelve-month figure through Jul 2025 stood at -$204.1 million (down 31.17% YoY), and the FY2025 full-year result was -$188.0 million, down 33.86% from the prior year.
- EBIT eased to -$59.0 million in Q3 2025, from -$55.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$12.7 million in Q1 2021 to a low of -$59.0 million in Q3 2025.
- A 5-year average of -$32.4 million and a median of -$28.0 million in 2023 frame the typical range for EBIT.
- Across the five-year window, EBIT advanced 0.53% in 2021 and sank 110.82% in 2022, its largest moves.
- Tracing KALV's EBIT over 5 years: stood at -$23.6 million in 2021, then slipped by 9.66% to -$25.9 million in 2022, then slipped by 14.92% to -$29.7 million in 2023, then slumped by 54.01% to -$45.8 million in 2024, then retreated by 28.81% to -$59.0 million in 2025.
- Business Quant data shows KALV's EBIT at -$59.0 million in Q3 2025, -$55.0 million in Q2 2025, and -$45.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -59.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -59.01 Mn |
| Apr 30, 2025 | -55.03 Mn |
| Oct 31, 2024 | -45.81 Mn |
| Jul 31, 2024 | -44.22 Mn |
| Apr 30, 2024 | -48.46 Mn |
| Jan 31, 2024 | -33.15 Mn |
| Oct 31, 2023 | -29.75 Mn |
| Jul 31, 2023 | -29.09 Mn |
| Apr 30, 2023 | -31.73 Mn |
| Jan 31, 2023 | -26.95 Mn |
| Oct 31, 2022 | -25.88 Mn |
| Jul 31, 2022 | -26.32 Mn |
| Apr 30, 2022 | -26.81 Mn |
| Jan 31, 2022 | -26.68 Mn |
| Oct 31, 2021 | -23.60 Mn |
| Jul 31, 2021 | -19.52 Mn |
| Apr 30, 2021 | -18.04 Mn |
| Jan 31, 2021 | -12.66 Mn |
| Oct 31, 2020 | -12.78 Mn |
| Jul 31, 2020 | -14.44 Mn |